ArticleClinical rheumatology2018
Brain magnetic resonance imaging, cerebrospinal fluid, and autoantibody profile in 118 patients with neuropsychiatric lupus.
Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Peripheral biomarkers of neuronal damage in neuropsychiatric systemic lupus erythematosus (NPSLE).Frontiers in cellular neuroscience · 2026Review
- The risk factors of cerebral small vessel disease in patients with Systemic Lupus Erythematosus.BMC rheumatology · 2025Article
- Multidisciplinary re-evaluation of neuropsychiatric events to confirm the neuropsychiatric lupus diagnosis at an Indonesian tertiary hospital.Lupus science & medicine · 2024Article
- Prediction model for developing neuropsychiatric systemic lupus erythematosus in lupus patients.Clinical rheumatology · 2024Article
- Article
- The conundrum of neuropsychiatric systemic lupus erythematosus: Current and novel approaches to diagnosis.Frontiers in neurology · 2023Review
- Cognitive changes mediated by adenosine receptor blockade in a resveratrol-treated atherosclerosis-prone lupus mouse model.Journal of traditional and complementary medicine · 2022Article
- Temporal and spatial changes in cerebral blood flow in neuropsychiatric systemic lupus erythematosus: a subtraction brain spect study.European journal of hybrid imaging · 2021Article
- Review
- Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China.Journal of immunology research · 2021Article
- Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations.European archives of psychiatry and clinical neuroscience · 2020Review
- [Autoantibody-associated schizophreniform psychoses: clinical symptomatology].Der Nervenarzt · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The objective of this study is to analyze clinical manifestations, features of imaging, and laboratory assessment of patients with neuropsychiatric SLE (NPSLE) for better diagnosis and outcome prediction. One hundred eighteen NPSLE patients admitted to the Anhui Provincial Hospital in Hefei, China, between January 2006 and December 2016 were enrolled and analyzed retrospectively. All patients fulfilled the American College of Rheumatology revised classification criteria for SLE. Patients with NPSLE fulfilled the American College of Rheumatology (ACR) nomenclature and case definitions. All NPSLE patients underwent neurological investigations including MRI of nervous system, electroencephalograms, or CSF examination as part of the diagnostic evaluation of nervous system involvement. All statistical analyses were performed. According to different types of data, different statistical methods were used to determine factors associated with abnormal MRI among NPSLE patients. Statistical significance was defined as P value < 0.05(two-tailed). Twelve different neurological manifestations of NPSLE patients were shown, in which headache was most common symptom (25.95%, 34/131), followed by seizures (25.19%, 33/131), cerebrovascular disease (18.32%, 24/131), psychosis (8.40%, 11/131), and others including mood disorder, cognitive dysfunction, plexopathy, cranial neuropathy, movement disorder, myelopathy, acute confusional state, and anxiety disorder. Thirteen patients have two neurological symptoms at the same time. Cerebrospinal fluid was assessed in 76 NPSLE patients, in which 29 patients had higher pressure of cerebrospinal fluid and 66 patients had abnormal immunoglobulin in cerebrospinal fluid, predominantly with an increase of IgG (84.21%, 64/76), followed by an increase of IgA (69.74%, 53/76), and IgM accounted for 47.74% (34/76). The MRI taken by 66.10% (78/118) patients have shown abnormal lesions and/or ischemic changes in the bilateral cerebral hemisphere, thalamus, pons, brainstem, and cerebellum. The abnormal changes in MRI were correlated with antiphospholipid antibody (APL) and C3 (P = 0.026 and 0.040, respectively). The most common clinical manifestation of NPSLE is headache, followed by seizures and cerebrovascular accident. The test of cerebrospinal fluid and MRI plays an important role in the assessment of NPSLE. The abnormal intracranial lesions were correlated with the level of anti-cardiolipin antibodies (ACL) and C3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.